Abstract
BackgroundAdelmidrol is a semisynthetic derivative of azelaic acid and analogue of the anti-inflammatory compound palmitoylethanolamide (PEA). Based upon its physicochemical properties, adelmidrol is suitable for topical application. The main objective of the present study was to evaluate the efficacy of a topical adelmidrol emulsion on early and late inflammatory responses in hypersensitive dogs. Repeated intradermal injections of Ascaris suum extract were performed in both lateral thoracic areas of six conscious hypersensitive Beagle dogs, topically treated during 8 consecutive days. Adelmidrol (2%) was applied to one side and vehicle to the other. 24 hours after the last antigen challenge, two biopsies (adelmidrol- and vehicle-treated side) were obtained for each dog at the antigen injection site.ResultsA significant reduction in the antigen-induced wheal areas was observed on the 4th and 7th day of adelmidrol treatment. Moreover, cutaneous mast cell numbers were significantly decreased in biopsies obtained after 8 consecutive days of topical adelmidrol treatment.ConclusionsThe results obtained in the present study show that topical treatment with adelmidrol might represent a new therapeutic tool in controlling the early and late allergic inflammatory skin responses in companion animals.
Highlights
Adelmidrol is a semisynthetic derivative of azelaic acid and analogue of the anti-inflammatory compound palmitoylethanolamide (PEA)
The present study shows, for the first time, that adelmidrol effects are evident in both the early phase reaction (EPR) and late phase reaction (LPR) in spontaneous hypersensitive Beagle dogs after intradermal antigen challenge
Practical considerations From a practical point of view, the present findings suggest that adelmidrol could find a place in the management of hypersensitive skin disorders in the dog, where topical treatments are currently preferred to systemic ones for localized lesions characterizing the less severe stages of the disease
Summary
Adelmidrol is a semisynthetic derivative of azelaic acid and analogue of the anti-inflammatory compound palmitoylethanolamide (PEA). The combined actions of newlysynthesized and preformed mediators released by MCs results in the subsequent transcription of inflammatory cytokines and chemokines that drive the recruitment of inflammatory cells to the site of antigen injection. This process is known as the late phase reaction (LPR) and can become chronic [31,32]. Based on the aforementioned background, the aim of the present study was to investigate whether, similar to PEA [33], adelmidrol was able to limit the inflammatory allergic response upon topical application
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
